3M Company Q2 2022 Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2022. The filing was signed July 27, 2022. Amounts are in U.S. dollars unless otherwise noted. The filing discusses several material developments announced after quarter-end.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $8.702B | $8.950B | $17.531B | $17.801B |
| Operating income | $110M | $1.971B | $1.751B | $3.965B |
| Operating margin | 1.3% | 22.0% | 10.0% | 22.3% |
| Net income attributable to 3M | $78M | $1.524B | $1.377B | $3.148B |
| Diluted EPS | $0.14 | $2.59 | $2.40 | $5.36 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $2.138B | $3.575B |
| Free cash flow | Not stated for quarter | Not stated for quarter | $1.330B | $2.871B |
Sales and margins: Q2 sales fell 2.8% year over year; organic sales grew 1.0%, offset by a 3.8% currency translation drag. First-half sales declined 1.5%, with 1.4% organic growth and a 2.9% translation drag. GAAP results were heavily affected by significant litigation costs. Excluding those items, 3M reported Q2 operating margin of 21.0% and diluted EPS of $2.48, versus 23.4% and $2.75 a year earlier; first-half adjusted margin was 21.2% and adjusted diluted EPS was $5.13, versus 23.7% and $5.70. These are company-defined non-GAAP measures.
Cash and debt: At June 30, cash and cash equivalents were $2.722B, and cash, cash equivalents and marketable securities totaled $3.011B. Total debt was $16.276B, compared with $17.363B at year-end 2021; net debt was $13.265B, up from $12.571B. Current assets of $14.514B exceeded current liabilities of $9.896B; working capital was $4.618B, down $1.750B from year-end. The $3.0B and $1.25B general credit facilities were undrawn; the company reported an EBITDA-to-interest covenant ratio of approximately 15:1 against a 3:1 minimum.
Cash generation and capital returns: First-half operating cash flow declined $1.437B year over year. Working-capital outflows from receivables, inventory and payables totaled $893M. Capital expenditures were $808M; dividends paid were $1.700B and treasury-stock purchases were $773M. First-half free cash flow conversion was 97%, compared with 91% a year earlier, using 3M’s non-GAAP definition.
Material changes and segment performance
- Q2 and first-half revenue declined despite modest organic growth, reflecting foreign-exchange headwinds, weaker personal-safety respirator demand, and business-specific demand and supply constraints.
- Q2 GAAP operating income fell to $110M, chiefly amid significant litigation charges, including a $1.2B pre-tax charge related to Combat Arms earplug and Aearo claims. 3M also recorded approximately $500M of pre-tax charges in the first half relating to PFAS matters at its Belgium site, including approximately $355M in Q2.
- Health Care was the only segment with positive reported sales growth in Q2 (+0.6%); organic sales rose 4.4%. Safety and Industrial sales declined 3.4%, Transportation and Electronics declined 3.7%, and Consumer declined 5.0%. All four segments reported lower operating income or margins year over year; Safety and Industrial’s GAAP operating loss included litigation costs.
- The stronger U.S. dollar reduced reported sales and earnings. Raw-material and logistics inflation, manufacturing productivity challenges, COVID-related restrictions in China, and disruption at the Belgium facility weighed on costs and operations.
Outlook, management commentary and key risks
- 3M estimated its 2022 effective tax rate at approximately 17.5%–18.5% and full-year capital spending at approximately $1.7B–$2.0B. It expected approximately $200M of 2022 cash contributions to global defined-benefit pension and postretirement plans. The filing text provided here does not give a clear full-year sales or EPS forecast.
- Management cited strong pricing, spending discipline and restructuring benefits, while noting inflation, supply-chain and manufacturing headwinds and increased investment in growth, productivity and sustainability.
- PFAS/environmental matters: In July 2022, 3M and the Flemish Government announced an agreement involving a total commitment of €571M, including prior commitments, concerning the Zwijndrecht site and related community and remediation matters. The company’s reported environmental accruals at June 30 included $754M for other environmental liabilities and $26M for non-PFAS environmental remediation. 3M said it could not estimate potential losses above established environmental accruals. Restart of key Belgium production processes had been approved, but continued oversight or inability to restart all processes could disrupt supply and operations.
- Combat Arms and Aearo: In July 2022, Aearo entities initiated Chapter 11 proceedings. 3M committed $1.0B to a trust for eligible claims and a further $0.2B for projected related expenses, with additional funding possible if required. The filing describes substantial litigation, adverse trial verdicts and appeals; the outcome and sufficiency of the funding are uncertain.
- Portfolio changes: In July, 3M announced its intention to complete the Food Safety business combination with Neogen through a split-off, subject to approvals and other conditions, and announced plans to spin off Health Care as a separate public company, initially retaining 19.9%. The Health Care transaction was expected by year-end 2023; completion and tax treatment were not assured.
- Other risks include ongoing PFAS litigation and regulation, respirator and product-liability claims, inflation and foreign exchange, the Russia-Ukraine conflict and related supply disruption, COVID-related impacts, and customer or supply effects from facility interruptions. 3M had suspended Russian subsidiary operations in March but continued to consolidate them as of June 30.
Most important facts for investors to verify
- How the $1.2B Combat Arms/Aearo charge and the July Chapter 11 process affect ultimate cash costs, litigation exposure and 3M’s funding obligations.
- Whether the €571M Belgium agreement and the $500M first-half PFAS charge fully capture expected commitments, and whether production can restart and remain compliant under the new permit.
- How much further PFAS-related environmental or litigation exposure could arise beyond recorded accruals; the filing says the excess loss range cannot currently be estimated.
- Whether underlying sales, margins and cash generation improve as inflation, currency effects, China restrictions and supply-chain constraints evolve; distinguish GAAP from adjusted results.
- Whether the Neogen split-off and proposed Health Care spin-off meet their conditions, timing and intended tax treatment, and what obligations or costs remain with 3M.